The association of Medicare Part D prior authorization for buprenorphine–naloxone with adherence to opioid use disorder treatment guidelines in the United States-Reference-Cited by-同舟云学术

The association of Medicare Part D prior authorization for buprenorphine–naloxone with adherence to opioid use disorder treatment guidelines in the United States

Published:2021-06-14 Issue:1 Volume:117 Page:141-150
ISSN:0965-2140
Container-title:Addiction
language:en
Short-container-title:Addiction

Author:

Parish William J.¹^ORCID,Mark Tami L.²^ORCID,Zarkin Gary A.¹,Weber Ellen³

Affiliation:

1. RTI International, Research Triangle Park NC USA

2. RTI International Rockville MD USA

3. Legal Action Center New York NY USA

Publisher

Wiley

Subject

Psychiatry and Mental health,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/add.15585

Reference26 articles.

1. AllenD.AHIP [internet].20202020/06/09/T11:34:23+0000. Available at:https://www.ahip.org/ahip‐survey‐prior‐authorization‐grounded‐in‐clinical‐evidence‐and‐selectively‐used/(accessed 7 June 2021).

2. The Effect of Formulary Restrictions on Patient and Payer Outcomes: A Systematic Literature Review

3. Association of Formulary Prior Authorization Policies With Buprenorphine-Naloxone Prescriptions and Hospital and Emergency Department Use Among Medicare Beneficiaries

4. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Buprenorphine Treatment For Opioid Use Disorder: Comparison Of Insurance Restrictions, 2017–21;Health Affairs;2023-05-01

2. Prior authorization restrictions on medications for opioid use disorder: trends in state laws from 2005 to 2019;Annals of Medicine;2023-02

3. Buprenorphine treatment episode duration, dosage, and concurrent prescribing of benzodiazepines and opioid analgesics: The effects of Medicaid prior authorization policies;Drug and Alcohol Dependence;2022-12